Fosamax and Osteonecrosis of the Jaw: Understanding the Risk and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Exposure Concerns

The legacy of general health and science information dissemination has long provided a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the communication of pharmaceutical safety data has evolved to address emerging concerns that bridge clinical medicine and broader environmental exposures. One such area of focus involves the relationship between bisphosphonate medications, commonly prescribed for bone density disorders, and rare but serious adverse events affecting the jaw. This intersection initially drew attention within clinical settings, where case reports and observational studies highlighted a potential association between prolonged use of drugs like Fosamax and the development of osteonecrosis of the jaw. As the scientific community examined these findings, the discussion naturally expanded beyond purely clinical parameters to consider how exposure pathways might extend into occupational environments. The transition from a general health framework to a more specific exposure concern is marked by a shift in emphasis: from patient-centered pharmacovigilance to the assessment of risk among workers who may encounter bisphosphonate compounds during manufacturing, handling, or disposal. This pivot requires careful consideration of exposure levels, duration, and routes that differ from therapeutic use, thereby necessitating a distinct analytical lens.

Bridging Clinical Evidence and Occupational Risk Assessment

The following discussion will explore how these occupational exposure scenarios align with or diverge from established clinical evidence, maintaining a neutral stance on mechanistic interpretations while focusing on risk characterization. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While Fosamax increases bone mass and reduces fracture incidence, its use has been associated with osteonecrosis of the jaw (ONJ), a condition involving bone death in the jaw that can occur spontaneously or be triggered by dental procedures. The clinical presentation of ONJ in patients taking bisphosphonates, including Fosamax, is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Temporal Patterns of ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Fosamax inhibits osteoclast activity, reducing bone turnover. Multiscale characterization of jawbone tissue has provided information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the antiresorptive effects of bisphosphonates, potentially leading to impaired healing and necrosis. Regarding the timeline between exposure and documented harm, the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping Fosamax, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Population-Level Risk and Duration of Exposure

Population-level data from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study underscores that while ONJ is a rare adverse effect, the risk increases with longer exposure to antiresorptive therapy. Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Clinical Guidance

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors. The label indicates that ONJ can occur spontaneously but is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ while on Fosamax should discontinue the drug if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate suggests a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence indicates that Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of therapy and in the presence of dental procedures or other risk factors. The prescribing information provides warnings and guidance for risk mitigation, including consideration of drug discontinuation for low-risk patients after 3-5 years and before invasive dental procedures. While absolute risk remains low, patients and clinicians should be aware of the potential for ONJ and monitor for symptoms.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the risk of developing osteonecrosis of the jaw (ONJ) from taking Fosamax?

The risk of ONJ from Fosamax is low, with absolute risks approximately 0.05% after 5 years of use. However, the risk increases with longer duration of therapy: it is threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Risk is also higher in patients undergoing invasive dental procedures or with other risk factors such as cancer, chemotherapy, or poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, reducing bone turnover. The jawbone may be particularly susceptible to this antiresorptive effect due to its unique structure and physiology, potentially leading to impaired healing and necrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). ONJ often occurs after dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the warning signs of osteonecrosis of the jaw?

Warning signs include pain, swelling, infection, loosening of teeth, delayed healing after dental procedures, and exposed bone in the mouth. Patients experiencing these symptoms while on Fosamax should consult their healthcare provider (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.